Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease

Journal of Natural Science, Biology and Medicine

Volumn 7, Issue 1, 2016, Pages 4-9

  Singh, Harmanjit ^a   Grewal, Nipunjot ^b   Arora, Ekta ^a   Kumar, Harish ^c   Kakkar, Ashish Kumar ^d  

^a GOVERNMENT OF INDIA   (India)

^b Punjab Institute of Medical Sciences   (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^d SAFDARJUNG HOSPITAL   (India)

Author keywords

Crohn's disease; inflammatory bowel disease; integrins; ulcerative colitis

Indexed keywords

EID: 84957547048     PISSN: 09769668     EISSN: 22297707     Source Type: Journal    
DOI: 10.4103/0976-9668.175016     Document Type: Review

References (30)

1. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864-75.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448:427-34.
3. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
4. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.e42.
5. Hanauer SB. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-9.
6. Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol 2010;25:453-68.
7. Bandyopadhyay S. Crohn's Disease: The Indian Perspective. Available from: http://www.apiindia.org/pdf/medicine-update-2012/ gastroenterology-01.pdf. [Last accessed on 2014 Jun 11].
8. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut 2003;52:1587-90.
9. Barreiro O, Sánchez-Madrid F. Molecular basis of leukocyteendothelium interactions during the inflammatory response. Rev Esp Cardiol 2009;62:552-62.
10. Matsuzaki K, Tsuzuki Y, Matsunaga H, Inoue T, Miyazaki J, Hokari R, et al. In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1. Clin Exp Immunol 2005;140:22-31.
11. Williams C, Panaccione R, Ghosh S, Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol 2011;4:237-48.
12. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005;1:CD003715.
13. Peyrin-Biroulet L, Lémann M. Review article: Remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:870-9.
14. Tysabri (Natalizumab) Intravenous Injection Monoclonal Antibody. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ UCM288126.pdf. [Last accessed on 2014 Jun 12].
15. WHO. International Nonproprietary Names for Pharmaceutical Substances. WHO Drug Information 2008;22:311-67.
16. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352: 2499-507.
17. Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012;18:1470-9.
18. Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1691-9.
19. Feagan B, Macdonald J, Greenberg GL. An ascending dose of a humanized alpha 4 beta 7 antibody in ulcerative colitis (UC). Gastroenterology 2000;118:A874.
20. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-7.
21. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
22. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
23. McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy 2012;4:883-98.
24. NIH. Study of Vedolizumab in Patients with Moderate to Severe Crohn's Diease (GEMINI III). Available from: http://www.clinicaltrials. gov/ct2/show/NCT01224171. [Last accessed on 2014 Jun 12].
25. NIH; An Open-Label Study of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease (GEMINI LTS). Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00790933. [Last accessed on 2014 Jun 12].
26. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011;3:76-99.
27. Takeda Submits Vedolizumab BLA". Available from: http:// www.dddmag.com/news/2013/06/takeda-submits-vedolizumabblaDrugDiscoveryandDevelopment. [Last accessed on 2014 Jun 11].
28. Takeda's New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis. Available from: http://www.takeda.us/newsroom/press-release-detail.aspx?id=285&year=2013. [Last accessed on 2014 Jun 11].
29. FDA Approves Entyvio to Treat Ulcerative Colitis and Crohn's Disease. Available from: http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm398065.htm. [Last accessed on 2014 Jun 11].
30. Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease. Available from: http://www.takeda.com/ news/2014/20140528-6590.html. [Last accessed on 2014 Jun 11].